Willem Mulder is a biomedical engineer, an inventor and entrepreneur. He develops innovative, bioengineered immunotherapies for cancer, inflammatory and cardiovascular diseases, and to prevent allograft rejection in organ transplantation. After acquiring a Ph.D. in biomedical engineering from the Eindhoven University of Technology (TU/e) in 2006, Mulder was recruited to the Icahn School of Medicine at Mount Sinai in New York. He founded Mount Sinai’s Nanomedicine Lab and became tenured Professor of Radiology and Professor of Oncological Sciences. Mulder published more than 200 papers in top scientific journals, such as Cell, Nature Nanotechnology, Nature Biomedical Engineering, Immunity, Science Translational Medicine. He was the principal investigator of multiple National Institutes of Health grants, including 3 R01s and a P01 Project from the Heart Lung and Blood Institute, a PO1 Project from the National Institute of Allergies and Infectious Diseases, as well as 2 R01s from the National Cancer Institute, and several co-investigator subawards. Besides his work at Mount Sinai, he held parttime professorships at the Amsterdam UMC (2012 – 2018) and at TU/e (2018 – present). In 2013, he received a Vidi grant and in 2018 he was awarded a Vici grant, both from the Dutch Science Foundation (NWO). In 2021, he was awarded an ERC Advanced Grant and returned to the Netherlands, where he established a research group spanning the Radboud University Medical Center and the Eindhoven University of Technology. 

Besides his academic activities, he co-founded Trained Therapeutix Discovery (ttxdiscovery.com), a biotech start-up that aims to treat detrimental immune-mediated diseases in 2019. He currently serves as the company’s Chief Scientific Officer. In the Netherlands, he initiated and co-founded the biotech incubator BioTrip (www.biotrip.nl) and the contract research organization Nanoworx (nanoworx.nl).